1. Home
  2. PSNL vs EMBC Comparison

PSNL vs EMBC Comparison

Compare PSNL & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$7.88

Market Cap

746.8M

Sector

Health Care

ML Signal

HOLD

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$10.46

Market Cap

755.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSNL
EMBC
Founded
2011
1924
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.8M
755.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
PSNL
EMBC
Price
$7.88
$10.46
Analyst Decision
Strong Buy
Buy
Analyst Count
6
2
Target Price
$11.17
$18.50
AVG Volume (30 Days)
1.4M
694.6K
Earning Date
02-26-2026
02-05-2026
Dividend Yield
N/A
5.52%
EPS Growth
N/A
138.19
EPS
N/A
2.36
Revenue
$69,103,000.00
$1,079,700,000.00
Revenue This Year
N/A
$2.00
Revenue Next Year
$19.41
$0.27
P/E Ratio
N/A
$4.61
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$9.20
52 Week High
$11.50
$18.12

Technical Indicators

Market Signals
Indicator
PSNL
EMBC
Relative Strength Index (RSI) 40.44 38.66
Support Level $7.27 $9.91
Resistance Level $9.79 $13.45
Average True Range (ATR) 0.86 0.76
MACD -0.28 -0.03
Stochastic Oscillator 14.89 15.84

Price Performance

Historical Comparison
PSNL
EMBC

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: